Albiglutide: First Global Approval
Authors:
- 27 May 2014
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 74 (8) , 929-938
Abstract
Albiglutide (Eperzan® [EU]; Tanzeum™ [US]), a glucagon-like peptide 1 receptor agonist, has been developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide has received its first global approval in this indication in the EU, for use in combination with other antihyperglycaemic agents, including basal insulin, when these drugs and diet and exercise do not provide adequate glycaemic control, and as monotherapy in patients unable to take metformin due to contraindications or intolerance when diet and exercise alone do not provide adequate glycaemic control. Albiglutide has subsequently been approved for the second-line or later treatment of T2DM as an adjunct to diet and exercise in the US. This article summarizes the milestones in the development of albiglutide leading to this first approval for the treatment of T2DM.Keywords
This publication has 12 references indexed in Scilit:
- Effects of Multiple Doses of Albiglutide on the Pharmacokinetics, Pharmacodynamics, and Safety of Digoxin, Warfarin, or a Low-Dose Oral ContraceptivePostgraduate Medicine, 2012
- Response to Comment on: Marquez et al. Low-Frequency Variants in HMGA1 Are Not Associated With Type 2 Diabetes Risk. Diabetes 2012;61:524–530Diabetes, 2012
- Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic reviewDiabetes, Metabolic Syndrome and Obesity, 2012
- Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic EfficiencyPLOS ONE, 2011
- Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?Diabetes, 2010
- Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitusCurrent Medical Research and Opinion, 2009
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 DiabetesDiabetes Care, 2009
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjectsDiabetes, Obesity and Metabolism, 2009
- Safet and tolerability, pharmacokinetic and spharmacodynamics of albiglutide in Japanese subjects with type 2 diabetes: a comparison with an ethnically mixed populationCanadian Journal of Diabetes, 2009
- A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose HomeostasisDiabetes, 2004